Lupin launches generic Tamiflu treatment capsules in US market

The company launched the tablets after receiving approval from USDAF

Press Trust of India  |  New Delhi 

drugs, medicines, USFDA
Photo: iStock

Drug firm Lupin today said it has launched in the US market its generic Phosphate capsules, used for treatment of The company said in a BSE filing that it has launched its tablets after receiving the approval from the Food and Drug Administration (USFDA). The capsules, in the strengths of 30 mg, 45 mg and 75 mg, are generic versions of Hoffman-La Roche Inc's Tamiflu capsules in the same strengths, it added. The product is "indicated for the treatment of acute, uncomplicated A and B in patients two weeks of age and older who have been symptomatic for no more than 48 hours, and prophylaxis of A and B in patients one year and older", Lupin said. The capsules had annual sales of about USD 518 million in the US as per IQVIA MAT December 201 data, it added. stock was trading 2.81 per cent higher at Rs 843.95 in the afternoon trade on BSE.

First Published: Mon, February 12 2018. 14:20 IST